- Research works
- 100 ▲ 507% vs 2013–17
- Citations
- 973 9.7 per fractional work
- Top-10% rate
- 15.3% record average 16.5%
- Open access
- 56% world 28%
Not ranked overall: Genome and Company (South Korea) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.9×. Every wedge is a field page.
- Biochemistry, Genetics and Molecular Biology 5.9×
- Immunology and Microbiology 4.6×
- Medicine 2.5×
- Pharmacology, Toxicology and Pharmaceutics 1.8×
- Neuroscience 1.7×
- Nursing 1.5×
- Chemistry 0.6×
- Materials Science 0.5×
- Agricultural and Biological Sciences 0.4×
- Energy 0.3×
- Environmental Science 0.2×
- Computer Science 0.2×
- Social Sciences 0.1×
- Engineering 0.1×
- Health Professions 0.1×
Which keywords describe research at Genome and Company (South Korea)?
By fractional works in 2022–2025, weighted toward what it does more of than the world: Cell-Free DNA, Targeted Therapy, Somatic Mutations, Cancer Genomics, Mutational Signatures, Cancer, Tumor Microenvironment and Inflammation.
- Fc Receptors
- Transcriptional Regulation
- Glycosylation
- PET Imaging
- Short-Chain Fatty Acids
- Gut Microbiota
- Neurodegeneration
- Clinical Trials
- Immune Responses
- Tumor Targeting
- Maternal Plasma DNA Sequencing
- Genomic Sequencing
- Inflammatory Diseases
- Oxidative Stress
- Angiogenesis
- Cancer Therapy
- Tumor Microenvironment
- Cancer Genomics
- Cancer
- Targeted Therapy
- Cell-Free DNA
- Inflammation
- Somatic Mutations
- Mutational Signatures
- Immunotherapy
- Prenatal Diagnosis
- Chemotherapy
- Immune Checkpoint Blockade
- PD-1 and PD-L1
- Aneuploidy Screening
- Precision Medicine
- Cancer Risk
- Microbial Communities
- Metabolism
- Gene Expression
- Metagenomic Analysis
- Breast Cancer
- Genetic Testing
- Stromal Cells
- Epigenetic Regulation
Size is fractional works in 2022–2025 in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 40 words, with their numbers
- Cell-Free DNA6▲ 108×2 topics
- Targeted Therapy5▲ 41×3 topics
- Inflammation5▲ 4.1×23 topics
- Cancer5▲ 6.0×22 topics
- Somatic Mutations4▲ 94×2 topics
- Cancer Genomics4▲ 105×1 topic
- Mutational Signatures4▲ 105×1 topic
- Tumor Microenvironment4▲ 16×6 topics
- Immunotherapy3▲ 7.1×7 topics
- Cancer Therapy3▲ 8.4×6 topics
- Prenatal Diagnosis2▲ 28×2 topics
- Angiogenesis2▲ 11×5 topics
- Chemotherapy2▲ 5.3×8 topics
- Oxidative Stress2▲ 2.2×14 topics
- Immune Checkpoint Blockade2▲ 32×1 topic
- Inflammatory Diseases2▲ 19×5 topics
- PD-1 and PD-L12▲ 32×1 topic
- Genomic Sequencing2▲ 27×2 topics
- Aneuploidy Screening2▲ 118×1 topic
- Maternal Plasma DNA Sequencing2▲ 118×1 topic
- Precision Medicine2▲ 6.2×6 topics
- Tumor Targeting2▲ 16×2 topics
- Cancer Risk2▲ 12×4 topics
- Immune Responses2▲ 20×2 topics
- Microbial Communities2▲ 6.5×3 topics
- Clinical Trials2▲ 3.8×7 topics
- Metabolism2▲ 5.0×8 topics
- Neurodegeneration2▲ 8.6×6 topics
- Gene Expression1▲ 4.0×6 topics
- Gut Microbiota1▲ 6.8×2 topics
- Metagenomic Analysis1▲ 19×1 topic
- Short-Chain Fatty Acids1▲ 19×1 topic
- Breast Cancer1▲ 8.4×4 topics
- PET Imaging1▲ 12×3 topics
- Genetic Testing1▲ 16×3 topics
- Glycosylation1▲ 17×2 topics
- Stromal Cells1▲ 24×2 topics
- Transcriptional Regulation1▲ 12×7 topics
- Epigenetic Regulation1▲ 8.2×3 topics
- Fc Receptors1▲ 32×1 topic
Which research topics does Genome and Company (South Korea) publish most on?
By volume in 2022–2025: Cancer Genomics and Diagnostics, Cancer Immunotherapy and Biomarkers, Prenatal Screening and Diagnostics and Gut microbiota and health.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Genomics and Diagnostics Cancer Research 4 works
- 2 Cancer Immunotherapy and Biomarkers Oncology 2 works
- 3 Prenatal Screening and Diagnostics Pediatrics, Perinatology and Child Health 2 works
- 4 Gut microbiota and health Molecular Biology 1 works
- 5 Peptidase Inhibition and Analysis Oncology 1 works
- 6 Monoclonal and Polyclonal Antibodies Research Radiology, Nuclear Medicine and Imaging 1 works
- 7 Advanced Computing and Algorithms Urban Studies 1 works
- 8 Nanoparticle-Based Drug Delivery Biomaterials 1 works
- 9 Thyroid and Parathyroid Surgery Surgery 1 works
- 10 Glioma Diagnosis and Treatment Genetics 1 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Genome and Company (South Korea)'s research output changed?
Output in 2018–2022 was 507% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in Seongnam-si
- Gachon University
- Seoul National University Bundang Hospital
- CHA University
- Korea Electronics Technology Institute
- CHA University Bundang Medical Center
- Language Science (South Korea)
- Hyundai Motors (South Korea)
- Naver (South Korea)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.